QPPV.COM KNOWLEDGE ASSESSMENT

Knowledge Assessment: Additional Risk Minimisation Measures

Test your understanding of the concepts covered by Additional Risk Minimisation Measures in the EU.

Question 1 of 10Pass mark: 80%

Question 1 of 10 Under which circumstance could discontinuation of an aRMM be considered?

The programme is expensive, regardless of its safety benefit Outcome evaluation shows no measurable benefit after a justified period and an alternative mitigation exists A vendor requests termination of its contract The programme has been operating for exactly three months

Question 2 of 10 Which lifecycle decision is most justified when process indicators remain below target and evidence shows the intervention does not address the actual risk driver?

Automatic discontinuation without analysis Modification of the content, distribution approach or target audience based on the new evidence Retention without further review Removal of the safety concern from the RMP

Question 3 of 10 Why are process indicators generally monitored from the time an aRMM is launched?

They provide early evidence of whether the intervention is being implemented and can identify operational failures before outcome data mature They prove clinical effectiveness without any outcome assessment They eliminate the need for baseline data They are used only to calculate vendor invoices

Question 4 of 10 A study measuring reduction in a rare adverse outcome is being planned. Which design consideration is particularly important?

Use an outcome definition without a statistical analysis plan Consider sample size, power, baseline comparisons, confounding and confidence intervals Measure only whether materials were mailed Set the success threshold after reviewing the final results

Question 5 of 10 Which approach best addresses a finding that prescriber certification is below its predefined threshold?

Delete the KPI so that future performance appears compliant Conduct root-cause analysis, implement documented remediation and verify improvement Wait until the next inspection before taking action Change the denominator retrospectively to exclude non-certified prescribers

Question 6 of 10 What is the primary basis for introducing an additional risk minimisation measure (aRMM)?

Routine measures alone are judged insufficient to control an important safety concern adequately The product has been commercially successful and requires broader communication A competitor has introduced an educational programme for a similar medicine The marketing authorisation holder wishes to increase prescriber engagement

Question 7 of 10 Why should patient-level records used in inspection extracts generally use hashed identifiers and restricted access?

To preserve confidentiality while allowing records to be linked and audited where necessary To prevent any review of monitoring or safety data To make the data appear less complete To remove the need for data processing agreements

Question 8 of 10 A vendor operates an enrolment portal for an aRMM. Which governance arrangement is most appropriate?

Delegation without a written agreement because the vendor is external A written contract defining responsibilities, KPIs and service levels, together with documented MAH oversight Complete transfer of accountability to the vendor Unrestricted vendor access to all patient and HCP data

Question 9 of 10 What is the main distinction between process and outcome indicators in aRMM evaluation?

Process indicators measure implementation, whereas outcome indicators assess whether the safety objective is being achieved Process indicators are always regulatory commitments, whereas outcome indicators are never commitments Process indicators concern only patients, whereas outcome indicators concern only healthcare professionals Process indicators are qualitative, whereas outcome indicators must always be quantitative

Question 10 of 10 A medicine has a contraindication in a narrowly defined patient group, but audits show frequent prescribing to that group despite clear routine product information. Which interpretation is most appropriate?

Routine measures may be insufficient, supporting consideration of a targeted aRMM No action is appropriate because the contraindication is already in the SmPC The product should automatically be withdrawn from the market The risk should be removed from the RMP because it is already characterised

Knowledge Assessment: Additional Risk Minimisation Measures

Cookie Settings